Improved detection of lung or bone metastases with an I-131 whole body scan on the 7th day after high-dose I-131 therapy in patients with thyroid cancer

Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 4, 2010, Pages 273-281

  Chong, Ari ^a   Song, Ho Chun ^a   Min, Jung Joon ^a   Jeong, Shin Young ^b   Ha, Jung Min ^c   Kim, Jahae ^a   Yoo, Su Ung ^a   Oh, Jong Ryool ^a   Bom, Hee Seung ^a  

^a Chonnam National University Medical School   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

^c Chosun University   (South Korea)

Author keywords

Distant metastasis; I 131; Post therapy scan; Scan time; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN;

ADULT; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG UPTAKE; FEMALE; HUMAN; IODINE 131 UPTAKE TEST; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; TREATMENT DURATION; WHOLE BODY SCINTISCANNING;

EID: 79952738688     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-010-0051-y     Document Type: Article

References (22)

1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-214.
2. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986;63:960-7.
3. Casara D, Rubello D, Saladini G, Gallo V, Masarotto G, Busnardo B. Distant metastases in differentiated thyroid cancer: long-term results of radioiodine treatment and statistical analysis of prognostic factors in 214 patients. Tumori. 1991;77:432-6.
4. Samaan NA, Schultz PN, Haynie TP, Ordonez NG. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab. 1985;60:376-80.
5. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-63.
6. Mazzaferri EL. Treatment of carcinoma of follicular epithelium. In: Ingbar SH, Braverman LE, editors. The thyroid: a fundamental and clinical text, 5th ed. Philadelphia: J.B. Lipincott; 1986. p. 1331.
7. Amdur RJ, Mazzaferri EL (2005) The value of a post treatment whole body scan. In Amdur RJ, Mazzaferri EL, editors. Essentials of thyroid cancer management. New York: Springer, pp 65-8.
8. Souza Rosário PW, Barroso AL, Rezende LL, Padrão EL, Fagundes TA, Penna GC, et al. Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? Clin Nucl Med. 2004;29:795-8.
9. Becker D, Charkes ND, Dworkin H, Hurley J, McDougall IR, Price D, et al. Procedure guideline for extended scintigraphy for differentiated thyroid cancer: 1.0. J Nucl Med. 1996;37:1269-71.
10. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941-59.
11. Němec J, Röhling S, Zamrazil V, Pohunková D. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med. 1979;20:92-7.
12. 131I. J Nucl Med. 2000;41:1198-202.
13. Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, et al. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med. 2001;28:639-45.
14. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892-9.
15. Mazzaferri EL. Empirically treating high serum thyroglobulin levels. J Nucl Med. 2005;46:1079-88.
16. Hindié E, Mellière D, Lange F, Hallaj I, de Labriolle-Vaylet C, Jeanguillaume C, et al. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging. 2003;30:974-81.
17. Hung BT, Huang SH, Huang YE, Wang PW. Appropriate time for post-therapeutic I-131 whole body scan. Clin Nucl Med. 2009;34:339-42.
18. Altman D. Practical statistics for medical research, 1st ed. London: Chapman & Hall/CRC; 1991. p. 403-7.
19. Khan S, Waxman A, Nagaraj N, Braunstein G (1994) Optimization of post ablative I-131 scintigraphy: comparison of 2 day vs. 7 day post therapy study in patients with differentiated thyroid cancer (DTC). J Nucl Med 35:15.
20. Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid. 2002;12:707-11.
21. Coakley AJ, Page CJ, Croft D. Scanning dose and detection of thyroid metastases. J Nucl Med. 1980;21:803-4.
22. Chung JK, Youn HW, Kang JH, Lee HY, Kang KW. Sodium iodine symporter and the radioiodine treatment of thyroid carcinoma. Nucl Med Mol Imaging. 2010;44:4-14.